The trials varied considerably in starting age (20 to 29 years), stopping age (38 to 64 years), and follow-up protocols
Cotesting vs Cytology Alone
Four RCTs (N > 130,000 women) compared screening with cytology alone vs cotesting (cytology in combination with hrHPV testing): the NTCC Phase I trial in Italy, 28,32,34 Swedescreen in Sweden, 36,37 A Randomized Trial in Screening to Improve Cytology (ARTISTIC) in the United Kingdom, 38-40 and the Population-Based Screening Study Amsterdam (POBASCAM) in the Netherlands. 41 In all 4 trials, the cumulative relative ratio of CIN 3+ detection between the 2 strategies (cotesting vs cytology alone) were not statistically significant after 2 rounds of screening. The NTCC Phase I, ARTISTIC, and POBASCAM trials reported 2 rounds of screening at 3- to 5-year intervals, whereas Swedescreen reported 1 round of screening with registry follow-up tajikistani beautiful women at 3 years. Two trials (Swedescreen and POBASCAM) reported no difference between screening strategies at 13 to 14 years of follow-up.
These 4 trials reported hrHPV positive rates of 7% to 22% for screening with cotesting; again, rates were highest among women younger than 30 or 35 years.Lire la suite »The trials varied considerably in starting age (20 to 29 years), stopping age (38 to 64 years), and follow-up protocols